title: Effects of the single and repeated administration of benazepril on systemic and forearm circulation and cardiac function in hypertensive patients.
abstract: The hemodynamic and cardiac effects of the new angiotensin-converting enzyme inhibitor, benazepril, were studied in 28 hypertensives in a double blind, placebo-controlled, between-patient study. Hemodynamic studies were performed noninvasively by means of M-mode echo (central hemodynamics and left ventricular systolic function), 2-D echo-Doppler (left ventricular diastolic function), and pulsed Doppler flowmetry (forearm circulation). Examinations were done at the end of a placebo run-in period and 3 hours after benazepril administration, both on the first day and after 6 weeks of treatment (10 or 20 mg once daily, according to patient response). In comparison with placebo, benazepril reduced systolic (p = 0.04) and diastolic (p = 0.003) blood pressure, because of a significant reduction in systemic vascular resistance (p = 0.03), while cardiac output was unchanged. Forearm vascular resistance was reduced and brachial artery compliance increased, although not to a statistically significant level (both p = 0.07). Both systolic and diastolic left ventricular function were positively influenced by the afterload reduction: End-systolic stress was reduced by 12% (p = 0.07), as was the late diastolic peak flow velocity (p = 0.02). All hemodynamic changes were evident after acute benazepril administration, and no differences was observed between acute and repeated treatment. We conclude that, similar to other ACE-inhibitors, benazepril reduces blood pressure through a reduction in vascular resistance, while cardiac output and heart rate are unaffected. These hemodynamic effects occur as early as after the first administration and exert a favorable influence on left ventricular dynamics.
authors.affiliation: Istituto di Clinica Medica I, II Facoltà di Medicina, Università di Napoli, Italy.
authors.forename: N
authors.initials: N
authors.lastname: De Luca
authors.forename: S
authors.initials: S
authors.lastname: Savonitto
authors.forename: B
authors.initials: B
authors.lastname: Ricciardelli
authors.forename: R
authors.initials: R
authors.lastname: Marchegiano
authors.forename: F
authors.initials: F
authors.lastname: Lamenza
authors.forename: G
authors.initials: G
authors.lastname: Lembo
authors.forename: B
authors.initials: B
authors.lastname: Trimarco
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001552:Benzazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D001775:Blood Circulation / Q000187:drug effects; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D005542:Forearm / Q000098:blood supply*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010919:Placebos
chemical_list: D000959:Antihypertensive Agents; D001552:Benzazepines; D010919:Placebos; C044946:benazepril